Sun Pharmaceutical Industries Ltd.

Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Vapi (a city in the southern Indian state of Gujarat). The company was listed on the Stock Exchange in 1994, and demand for its shares oversubscribed 55 times.

At the present time Sun Pharma is the second largest and most profitable pharmaceutical company in India, as well as the largest pharmaceutical company by market capitalization of the Indian stock exchanges.

Sun Pharma has 26 production platforms, including the US, Canada, Brazil, Mexico and Israel.

The company employs more than 14,000 employees, and during the whole period of existence released more than 1000 different kinds of products.

72 % Sun Pharma sales are to markets outside India, especially in the United States. United States – the largest market, accounting for about 54 % of the turnover as a whole.

But in this market, the company produces only those generics, which approved FDA. April 6, 2014 was held the historic deal, estimated at $ 4 billion – the company announced that it will acquire 100 % stake in Ranbaxy Laboratories Ltd. The Japanese company Daiichi Sankyo has a 63.4 % stake in Ranbaxy.

In 2015:

• acquires GSK’s Opiates business in Australia;
• acquires InSite Vision Inc. to strengthen branded ophthalmic portfolio in USA;
• enters into research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies.